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Abstract 
The goal of topical and cutaneous delivery is to deliver therapeutic and other substances to a 
desired target site in the skin at appropriate doses to achieve a safe and efficacious outcome.   
Normally, however, when the stratum corneum is intact and the skin barrier is 
uncompromised, this is limited to molecules that are relatively lipophilic, small and 
uncharged, thereby excluding many potentially useful therapeutic peptides, proteins, 
vaccines, gene fragments or drug-carrying particles.  In this review we will describe how 
nanosystems are being increasingly exploited for topical and cutaneous delivery, particularly 
for these previously difficult substances.  This is also being driven by the development of 
novel technologies, which include minimally invasive delivery systems and more precise 
fabrication techniques.  While there is a vast array of nanosystems under development and 
many undergoing advanced clinical trials, relatively few have achieved full translation to 
clinical practice.  This slow uptake may be due, in part, to the need for a rigorous 
demonstration of safety in these new nanotechnologies.  Some of the safety aspects 
associated with nanosystems will be considered in this review. 
 
 
Keywords:  topical delivery, cutaneous delivery, nanosystems, nanoparticles, colloidal 
nanocarrier systems  
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1. Introduction  
There has been great interest in nanosystem facilitated delivery of therapeutic, diagnostic, 
prophylactic or cosmetic substances into the skin, in which the goal is to overcome the skin 
barrier in a controlled manner to reach targets in various skin layers, including the stratum 
corneum, as well as deeper tissues, or systemically.  On the other hand, nanomaterials are 
also applied directly to the skin, for example, when titanium or zinc oxide are used as 
sunscreens. Here, the intention is not to penetrate the stratum corneum, but to deliver the 
nanomaterials so that they remain on the skin surface. In this review, we will examine some 
of the various nanosystems currently in use, with particular reference to their ability to 
penetrate the skin barrier.  Table 1 summarises the scope of the field of topical and cutaneous 
delivery using nanosystems and Table 2 gives a more detailed summary of the properties of 
some of the nanodelivery systems to be discussed later in this review. The range of 
particulate nanosystems under investigation is illustrated in Figure 1.  Some of the 
applications of topically applied nanodelivery systems for treatment of skin disorders are 
listed in Table 3.  
 
2. The stratum corneum barrier problem 
The skin plays a major role in protecting the body from the surrounding environment by 
providing a highly efficient barrier to the penetration of exogenous molecules and micro-
organisms, and maintaining homeostasis by preventing excessive loss of water [38].  A 
simplified representation of human skin containing its major structures and cell types is 
illustrated in Figure 2. Although the location of the barrier within the skin was long debated, 
Scheuplein showed conclusively in 1966 that it largely resided in the stratum corneum [39], 
due to its unique structure, most simply described as a series of layers of flattened 
corneocytes surrounded by a lipid envelope.  The most likely route taken by a substance in 
penetrating the stratum corneum is via a tortuous pathway through the lipids surrounding the 
corneocytes (intercellular route) [40], although the transcellular route though the corneocytes 
may be viable under certain circumstances [41].  The stratum corneum is also traversed by 
pilosebaceous units (hair follicles and associated sebaceous glands) and sweat glands. While 
the average follicular orifice area on the human skin surface is only about 0.1% of the total 
surface area [42], under some circumstances these appendages may be potential routes of 
entry into the skin [43], as we shall discuss later.  
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The fundamental question facing those who seek to develop formulations for topical or 
transdermal delivery is; how can a particular active be made to overcome the formidable 
stratum corneum barrier,   
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so that it can be delivered to the site of action in sufficient quantities to achieve a desired 
therapeutic effect, with the least possible adverse effects?  The range of substances that are 
suitable for diffusion through the stratum corneum is generally limited to those that are 
relatively small (< ~500 Da), lipophilic (log 1 – 3) and water soluble [44].  Given the 
generally low permeation rates for most molecules, they must also be highly potent [45].  
Clearly, there is a vast array of attractive prospects for topical application such as peptides, 
proteins, vaccines, nucleotide fragments or powerful cancer therapeutics that do not fit these 
criteria.  This dilemma has been a major factor in the interest in nanodelivery systems that 
could expand the range of active molecules that are available for therapeutic or other 
purposes. 
 
3. Solid nanoparticles 
In the early 1900s, Ehrlich introduced the concept of drug targeting using a delivery system 
he called „Zauberkugeln‟ (Magic Bullets) [46].  This was put into practice in the 1950s and 
1960s with the development of miniaturised delivery systems, focusing initially on 
polyacrylic beads for oral delivery, with the first nanoparticles for vaccination purposes 
appearing in the late 1960s [47]. By 1978, the field was sufficiently advanced for the first 
review article on nanoparticles as new drug delivery systems to be published [48].  In 1994, 
nanoparticles were defined for pharmaceutical purposes in the Encyclopaedia of 
Pharmaceutical Technology as “solid colloidal particles ranging in size from 1 to 1000 nm. 
They consist of macromolecular materials and can be used therapeutically as drug carriers, in 
which the active principle (drug or biologically active material) is dissolved, entrapped, or 
encapsulated, or to which the active principle is adsorbed or attached” [49].  Later 
developments saw the use of nanoparticles for intravenous cancer therapy, with Brasseur et 
al. reporting an enhanced efficacy of actinomycin D absorbed on polymethylcyanoacrylate 
nanoparticles against an experimental subcutaneous sarcoma [50], taking advantage of their 
enhanced permeability and retention effects [51]. The first commercial nanoparticle product 
containing a drug appeared on the US market in 2005. This contained an injectable 
suspension of human serum albumin nanoparticles containing paclitaxel (Abraxane
®
, Abraxis 
BioScience, now Celgene Corporation, Los Angeles, CA, USA) and was indicated for the 
treatment of metastatic breast cancer [52].   
 
The first reported topical applications of nanoparticles were to the eye, when Li et al. treated 
albino rabbits with polymeric nanoparticles encapsulating progesterone in 1986 [53]. 
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However, it was not until the end of the 20
th
 century that reports on the application of 
nanoparticles to skin for vaccination [54] and vitamin A delivery [55] appeared in the 
literature.  In the short time since, the topical application of a range of nanomaterials has been 
investigated.  Of interest in this review are such materials as quantum dots, metal particles 
(gold, silver and beryllium), metal oxides (TiO2, ZnO, carbon nanotubes and organic 
fullerene derivatives [1, 56-64]. These are relevant because, as we have already seen, 
nanosystems are not only potential drug delivery vectors, but some have also been suspected 
of causing harmful effects on the skin. For instance, it has been proposed that surface-coated 
quantum dots could be used to carry drugs into the skin [65]. Similarly, drug-coated particles 
could be targeted to appendages such as hair follicles, where their payloads could be released 
slowly into local sites or into the systemic circulation [66]. Conversely, the unwanted 
penetration of nanoparticles through occupational or environmental exposure [64], or through 
absorption of nano sunscreen substances could have toxic consequences [67]. 
 
3.1. Factors affecting skin penetration of solid nanoparticles 
The properties of nanoparticles that could influence penetration of nanoparticles through the 
stratum corneum, as well as potential deposition in furrows, appendages and deeper skin 
layers include size (both in the native state and in conjunction with associated water or other 
solvent molecules), shape, charge and surface properties such as coatings or functional 
groups, as well as their aggregation state [68]. In addition, the vehicle in which the particles 
are suspended can have an influence by altering the properties of the nanoparticles 
themselves [69] or by affecting the permeability of the stratum corneum [58]. Furthermore, 
the condition of the skin, including the presence of an altered or impaired barrier due to 
specific skin diseases may affect the degree and depth of nanoparticle penetration [70, 71]. A 
summary of the factors influencing the skin penetration of nanoparticles, as well as the 
potential routes of delivery is illustrated in Figure 3.  
 
In evaluating the large volume of literature on nanoparticle skin penetration, it is important to 
be aware of the experimental conditions under which the studies were carried out. This is 
highlighted in Figure 4 which shows the wide variation in penetration of various gold based 
nanoparticles through excised skin from rats [72], pigs [73] and humans [58, 74, 75].  Figure 
4 shows that rat and pig skin was highly permeable to even large (~200 nm) particles, 
whereas the 161 nm gold/silica particles applied to human skin remained on the surface or 
penetrated into follicles [74]. Moreover, in the studies by Labouta et al, [58, 75], human skin 
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penetration was size and vehicle-dependent. The 6 nm particles penetrated readily from 
aqueous buffer or toluene, as expected for such a small diameter [68, 70]. The 15 nm 
particles applied in aqueous buffer, accumulated in the skin furrows, but in toluene, which 
could potentially damage the skin barrier, they were detected in the lower epidermis.    
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3.1.1. Quantum dots (QDs)  
These are small spherical or ellipsoidal particles, generally less than 20 nm on the major axis, 
with a metal core, an outer shell and various coatings or functional groups attached to the 
surface. Penetration of QDs has been studied in ex vivo rat, weanling pig and human skin. In 
contrast to the previous suggestions [65, 76], little compelling evidence of quantum dot 
penetration in intact skin has been found to date. In 2006, Ryman-Rasmussen [63] used a 
range of QDs with different shapes and surface charges, applied to dermatomed weanling pig 
skin in buffers at pH 8.3 or 9.0. The QDs were found to be localized within the viable 
epidermis by 8 or 24 hrs, but none penetrated into the receptor of the flow-through cells used.  
The authors concluded that significant penetration through the stratum corneum and into the 
viable tissue was possible with these small particles. Later, Prow et al [61] repeated some of 
Ryman-Rasmussen‟s key experiments using excised human skin in order to examine the 
possibility that the penetration seen previously [63] may have been influenced by an 
immature barrier in weanling pig skin.  The results, shown in Figure 5, indicate that at neutral 
pH none of the QDs penetrated beyond the stratum corneum and remained accumulated in the 
skin furrows.  On the other hand, they did observe some penetration of the neutral PEG-
coated particles to the viable epidermis at pH 8.3 [61] and suggested that the elevated pH 
may indeed cause a weakening of the stratum corneum barrier, in support of Ryman-
Rasmussen‟s findings [63] and others [77].  When 30 tape strips were applied to intact skin to 
physically disrupt the barrier, all QDs penetrated as far as the upper dermis by 24 hrs [61]. 
Zhang et al. [78] performed similar studies in rat skin using the same anionic QDs used by 
Ryman-Rasmussen, as well as with different QDs (nail shaped, PEG coated) in dermatomed 
weanling pig skin [79]. Interestingly, they saw no penetration of these QDs in intact rat or pig 
skin, nor did they detect penetration in flexed or tape stripped rat skin. There was, however, 
minimal QD penetration into abraded rat skin at 8 or 24 hrs. Taken together, these findings 
support the notion that while QDs may be able to penetrate a weakened or disrupted stratum 
corneum barrier to some extent, they are unlikely to penetrate intact human skin under 
normal conditions. 
 
3.1.2. Effects of a stressed or compromised skin barrier 
We have already seen that even under quite severe treatment such as tape stripping, the skin 
barrier is able to limit the penetration of small nanoparticles like QDs. In everyday life 
however, human skin is subject to a range of insults and stresses. For example, Tinkle et al 
[64] have argued that if skin is exposed to particulate material during repetitive movement or 
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mechanical stress, such as might occur in an industrial situation, or regularly walking 
barefoot, penetration of those particles may be enhanced. This led them to suggest that the 
skin was a route of exposure in industrial chronic beryllium disease, while further support 
came from observations of elephantiasis in individuals in certain regions in Africa, associated 
with penetration of clay particles through bare skin of their feet [80]. To test this, they 
investigated the effect of mechanical flexing on particle penetration in excised human skin 
and showed that 30 – 60 minutes of mechanical flexing led to the penetration of 0.5 and 1.0 
m FITC-dextran particles as far as the viable epidermis and occasionally to the dermis, as 
shown in Figure 6.  
 
While these fluorospheres are far larger than the nanoparticles discussed above, Rouse et al 
found that very small fullerene-substituted nanoparticles (about 3.5 nm) also penetrated into 
the dermis of dermatomed pig skin by 8 hrs after 60 min mechanical flexing [62]. This 
contrasts with the lack of penetration of the somewhat larger QDs through flexed rat skin 
noted above [78]. 
 
3.1.3. Zinc oxide (ZnO) skin penetration 
Nano-sized zinc oxide particles are commonly used in sunscreens to protect against the 
effects of UV radiation and are also subject to the same mechanical and repetitive stresses 
that are imposed upon skin during normal activities, as discussed above. This prompted 
concern about whether the nanoparticles could penetrate the skin barrier and access the viable 
epidermal cells [81-83], particularly in view of in vitro evidence suggesting that ZnO 
nanoparticles are internalized by cultured human keratinocytes and cause cytotoxic and 
genotoxic responses [84]. 
 
In an early in vitro study by Cross et al. in 2007 [56], sunscreen formulations containing 
micronized ZnO nanoparticles (15-40 nm) were applied to human epidermal membranes in 
Franz cells for 24 hours. Electron microscopy showed that the nanoparticles were confined to 
the surface and loose outer layers of the stratum corneum, with none detected in the lower 
stratum corneum or viable epidermis. Surprisingly however, they found evidence to suggest 
Zn penetration though the membrane, with a trend towards increased Zn levels in the receptor 
medium, detected by ICP-MS, although the differences were not significant.  In an analogous 
in vivo study, Gulson et al. [57] also reported penetration of Zn through human skin.  
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Sunscreens containing ZnO with >99% of the stable isotope 
68
Zn, to distinguish from 
naturally occurring Zn, were applied to human volunteers under in use beach conditions over 
five consecutive days and small but significant amounts of 
68
Zn were detected in blood and 
urine of volunteers by ICP-MS.  Neither of these studies therefore provided direct evidence 
of intact ZnO penetration beyond the outer skin layers and it is likely that the Zn detected by 
ICP-MS was ionic Zn
2+
 ions that penetrated following hydrolysis of ZnO on the skin surface.  
In support of the hydrolysis mechanism, the skin surface is known to be relatively acidic, 
particularly with moderate sweating as might be experienced in association with sunscreen 
use outdoors [85] and significant amounts of Zn
2+
 have been shown to be released from 4 nm 
ZnO nanoparticles at pH 1, 3 and 6 [86].  More direct evidence of increased labile Zn
2+
 
penetration was recently reported by Holmes et al [87], after application of ZnO nanoparticles 
suspended in oil (capric caprylic triglycerides, or CCT) or water (pH 6 and 9).  Zn
2+
 was 
detected in the stratum corneum and viable epidermis by imaging the fluorescence due to the 
complex formed between Zn
2+
 and the labile zinc selective probe Zinpyr-1, with the highest 
levels occurring with the pH 6 application. 
Notwithstanding the in vivo findings above [57], it is generally accepted that passive 
penetration of ZnO nanoparticles into intact human skin is limited to the surface and upper 
layers of the stratum corneum [56, 88].  However, the question remains whether penetration 
can occur when the barrier is compromised, or when then skin is stressed or manipulated in 
normal activities.  We have reported findings with in vivo ZnO nanoparticle applications in 
massage and flexing [59], occlusion of the skin surface [1], barrier disruption [1, 59, 89], and 
skin conditions such as psoriasis and atopic dermatitis LL [89], where both nanoparticle 
penetration and metabolic changes to endogenous fluorophores in skin (representing toxicity) 
were assessed by multiphoton tomography with fluorescence lifetime imaging (MPT-FLIM).  
The particles used in this work were characterised to be less than 200 nm in size and either 
bare, or with a siloxane coating.  In none of these studies was there any significant evidence 
of penetration of nanoparticles into the viable epidermis or deeper.  Unlike the evidence of 
microparticle penetration in excised human skin shown by Tinkle et al. [64] seen in Figure 6, 
MPT images of flexed in vivo human skin following application of bare (uncoated) and 
siloxane coated ZnO nanoparticles [59] show that all ZnO was confined to the skin surface, 
furrows and the upper layers of the stratum corneum (Figure 7).  
 
Similar results were obtained with massage [59] (Figure 7) and occlusion of the skin [1] 
(Figure 8)  No evidence of epidermal cytotoxicity due to effects of ZnO on NAD(P)H and 
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FAD fluorescence lifetimes was seen with any of these treatments [1, 59]. Similarly, Figure 9 
shows that ZnO nanoparticles applied to psoriatic lesions in human patients also fail to 
penetrate into the viable epidermis and remain largely accumulated in the furrows. 
 
In other work examining nanoparticle penetration with a compromised skin barrier, 
Monteiro-Riviere et al. applied ZnO and titanium dioxide (TiO2) products to the skin of UVB 
sunburnt pigs in vivo and in vitro [60].  They observed minimal penetration of ZnO and TiO2, 
only into the upper layers of the viable epidermis and found no evidence of systemic 
absorption. 
 
While this evidence about safety of ZnO nanoparticles is fairly convincing, particularly for 
intact skin, it should be recognised that the results obtained for compromised skin in 
relatively common conditions like psoriasis and atopic dermatitis, or in sunburn, are limited.  
Further work in this area is warranted, but the enormous benefits of sunscreens in protecting 
against skin cancer should not be overlooked when assessing the potential risks of 
nanoparticle application to the skin.  Relevant to this debate is a recent study by Ryu et al. 
[90], who applied up to 1000 mg/kg of a suspension of 29 nm ZnO nanoparticles to the skin 
of rats daily for 90 days.  No evidence of toxicity was found, based on clinical examination, 
haematology, blood and urine biochemistry and histological analysis of tissues.  ZnO 
accumulation in the liver, intestines and faeces was thought to be due to ingestion. 
 
3.2. Follicular delivery of nanoparticles 
In deliberate attempts to promote skin delivery, the Lademann group has used massage to 
deliver nanoparticles of optimal sizes of 300 – 600 nm deep within the follicle. They showed 
that although an intact and relatively impermeable stratum corneum similar to that of the 
interfollicular epidermis covers the acroinfundibulum (the upper portion of the follicle as it 
enters the epidermis), this barrier is interrupted in the lower follicular infundibulum. The 
corneocytes in this area appear smaller and crumbly, suggesting that the skin barrier is 
permeable and provides an opportunity for interactions between topically applied compounds 
and the hair follicle epithelium [91].  Interestingly, this particle size matches the cuticula 
thickness on human (530 nm) and porcine (320 nm) hair, so the suggestion is that hair 
movement during massage allows the cuticulae to engage with the matching particles like a 
geared system, driving them deep into the follicle [66, 92, 93].  The ability to target 
nanoparticles to different depths in the follicle, depending on their size may allow treatment 
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of different site-specific conditions.  In addition, 320 nm particles have been shown to reside 
in the follicle for up to 10 days, indicating that the follicle could act as a reservoir for long 
term storage and release of drugs delivered in association with nanoparticles [94]. Trauer et 
al. [95] also used massage and occlusion to enhance follicular penetration of liposomal 
systems in ex vivo human skin.  Massage was found to enhance the follicular penetration of 
rigid and flexible liposomes significantly, while occlusion was favoured only for the rigid 
liposomes. 
 
Vogt et al. [96], also from the Lademann group in Berlin, showed that after cyanoacrylate 
stripping to remove the contents of human vellus hair follicles followed by massage, 40 nm 
particles could be targeted deep within the follicle and through the follicular epithelium, to be 
internalized by Langerhans cells surrounding the follicles [97], whereas 750 and 1500 nm 
particles remained in the infundibulum and were not internalized, as shown in Figure 10.  
 
These workers suggested that the small nanoparticles could be an efficient delivery system 
for vaccine delivery to cutaneous antigen-presenting cells illustrated in Figure 2.  They 
expanded these concepts in recent work [98], showing that larger 200 nm nanoparticles also 
penetrated deeply with massage into human vellus and intermediate hair follicles after a 
single cyanoacrylate treatment to remove follicular contents.  Moreover, the cyanoacrylate 
treatment was associated with clear signs of activation and migration of dendritic cells 
indicated by retraction of dendrites, reduction of LC numbers in the epidermis with 
concomitant increases in the dermis surrounding the follicles and expression of activation 
markers.  Their work suggests that follicular delivery combined with immune activation 
would be a viable technique to promote uptake of topical antigens.  
 
Other nanodelivery systems investigated for follicular delivery include lipid nanocarriers [95, 
99-104], nanoemulsions [105-107] and polymeric vesicles [108-111].  The Hoffman group in 
San Diego used a phosphatidylcholine-based liposome system to deliver proteins, genes, 
melanin and small molecules selectively to the pilosebaceous unit in mice, with negligible 
amounts detected in the epidermis, dermis or systemic circulation [101-104].  These 
nanosystems will be discussed in more detail below, with regard to delivery through the 
stratum corneum barrier. 
 
4. Colloidal nanocarrier systems 
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These have been increasingly exploited for dermatological, cosmetic and personal care 
applications. Common colloidal nanosystems include the liquid emulsions (microemulsions 
and nanoemulsions) (NE), solid lipid nanoparticles (SLN), nanostructured lipid carriers 
(NLC) and advanced nanovesicles such as flexible and ultraflexible liposomes. These 
formulations can offer increased efficacy and targeted delivery, improved bioavailability and 
stability of the active, reduced irritancy, and facilitate the formulation of lipophilic, poorly 
water-soluble compounds.   
 
4.1. Emulsions 
Microemulsions were first described scientifically by Hoar and Schulman in 1943 [112].  
They noted that coarse macroemulsions stabilized with an ionic surfactant became 
transparent on addition of a medium chain length alcohol, a co-surfactant. After originally 
referring to these systems as hydrophilic oleomicelles or oleophilic hydromicelles, Schulman 
et al. introduced the term „microemulsion‟ in 1959 [113]. It was not until the 1980s that the 
potential use of microemulsions as topical formulations for skin delivery was explored [114, 
115]. 
 
4.1.1. Nanoemulsions (NE) for skin delivery 
Nanoemulsions are dispersions of oil and water phases stabilised by surfactants, with mean droplet 
diameter in the submicron range [116, 117]. They can be formed by high-energy and low-energy 
emulsification techniques [118] and typically contain a relatively low percentage of surfactant [119]. 
The small droplet size results in a kinetically stable system that resists destabilisation due to 
gravitational separation, flocculation and coalescence [119], and is transparent or translucent. The 
low surfactant content offers advantages in topical application with reduced irritancy to the skin.  
The small droplet size provides a large surface area and uniform distribution on the skin, good 
occlusiveness, film formation, aesthetic qualities and skin feel [120, 121].  NEs have wide application 
in the pharmaceutical and cosmetic industries for indications including inflammation, anti-aging, 
moisturisation and beauty [122].  They have particular utility in the management of chronic skin 
diseases such as atopic dermatitis or dry skin, to provide skin protection and hydration, without 
irritating or weakening the skin barrier [123].  NEs can enhance permeation into the skin by a 
number of mechanisms. First, they provide a high solubilisation capacity for both lipophilic and 
hydrophilic compounds, thereby increasing the loading capacity and dose application of the 
formulation. Second their large surface area and good skin contact, coupled with their occlusive 
nature ensures good surface contact with the stratum corneum surface. Third, their oil and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 14 
surfactant components may have a direct permeation enhancement effect on the stratum corneum 
lipid structure [Krielgard ref from main list]. A recent review provides a summary of the 
dermatological applications of NEs [122].  
 
We showed significantly enhanced flux of the hydrophilic caffeine and lipophilic naproxen across 
human epidermis in vitro [34]. The NE oil phase was composed of the skin penetration enhancers 
oleic acid or eucalyptol with the aim of investigating a synergistic effect of the increased surface area 
and contact with the skin, enhanced solubility and direct chemical enhancement effects of the oil 
excipients within the stratum corneum. There was only a modest increase in caffeine solubility 
within the stratum corneum, therefore the increase in skin diffusivity that contributed to the 
maximum flux enhancement resulted primarily from the direct effect of the NE excipients reducing 
the diffusional resistance for caffeine penetration within the stratum corneum. In contrast, 
increased flux of the lipophilic naproxen was primarily due to formulation-increased solubility of 
naproxen in the stratum corneum, with only a modest increase in diffusivity.  
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4.2. Lipid-based colloidal nanosystems 
4.2.1. Solid lipid nanoparticles (SLN) 
SLN were developed in parallel in Germany [124] and Italy [125], in the early 1990s. They 
are composed of lipids, lipid-like materials or a mixture with a diameter from 10 nm to 10 
µm, are solid at ambient temperature and able to incorporate active agents into their solid 
core for various delivery applications (e.g. parenteral, enteral, pulmonary and topical) 
resulting in a controlled release over a long period of time [126]. They are normally prepared 
by high-pressure homogenization and offer the opportunity to formulate hydrophobic actives 
such as vitamin A, vitamin E [127] and coenzyme Q10 in cosmetically elegant products, 
rather than an ointment with poor aesthetic qualities and consumer acceptability. They can 
also increase the stability of compounds such as retinol that are prone to decomposition in the 
presence of light and oxygen [55, 128] and provide controlled delivery of actives to the skin. 
For example Zhang et al [129] showed higher stratum corneum deposition but lower flux of 
aconitine from SLN compared with a nanoemulsion emulsion of similar sized vesicles (70-90 
nm). SLNs form a film on the skin surface that combines with the skin lipid film to reduce 
water loss, increase skin hydration and help protect the barrier function of the stratum 
corneum [130, 131]. Good skin adherence is particularly useful in sunscreen products where 
wash off due to sweating and bathing can lead to unforeseen sunburn. Enhanced stratum 
corneum permeation is attributed to multiple mechanisms: prolonged contact with the skin 
surface; the occlusive nature of the SLN formulation hydrating the skin [8]; and interaction 
between formulation lipids and stratum corneum lipids facilitating permeation of lipid soluble 
compounds.   chler et al [132] used scanning electron microscopy to show the loss of SLN 
platelet structure 2h after administration on the surface of pig skin. Evidence of the 
interaction between cetyl palmitate SLN formulation lipids and stratum corneum lipids were 
demonstrated by shifts of phase transition temperature (differential scanning calorimetry) and 
stretching bands (Fourier transform infrared spectroscopy) [133]. Zhang et al [134] observed 
that this interaction was highly formulation dependant as prolonged and localized delivery of 
betamethasone 17-valerate could be achieved with monostearin SLN but not with other lipids 
such as beeswax. The cationic phospholipids 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP) and dioleoylphosphatidylethanolamine (DOPE) provide the potential for charge 
interaction with the negatively charged skin surface. Highly positively charged (51 mV) SLN 
using DOTAP, DOPE, Tween 20 as surfactants, tricaprin as a solid lipid core, and 
encapsulating plasma DNA, showed enhanced in vitro permeation into mouse skin and 
expression of mRNA in vivo in mice after topical application [135]. 
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4.2.2. Nanostructured lipid carriers (NLC) 
The second generation of SLN, nanostructured lipid carriers (NLC) appeared in 1999 with the filing of 
the US patent by the German company PharmaSol GmbH. These nanoparticles showed improved 
drug loading and stability of long-term incorporation [136]. As with liposomes, the introduction of 
NLC was into the cosmetic market, aided by lower regulatory hurdles, with the launch of Cutanova 
Cream Nano Repair Q10 and Intensive Serum NanoRepair Q10 by Dr. Rimpler GmbH (Germany) in 
October 2005 [137, 138].  
 
NLC are composed of a fluid lipid phase embedded into a solid lipid matrix [126] or localized at the 
surface of solid platelets and the surfactant layer [139]. The lipids spatial structure allows greater 
drug loading and better stability compared to SLN [140]. For example the sunscreen loading capacity 
of 70% in NLC compared to 10-15% in SLN, allows the development of suncare products with higher 
sun protection factor (SPF) [141]. Chen et al [142] showed improved stability of Coenzyme Q10 in 
NLCs compared to an emulsion or ethanol formulation (decrease of 5.59%, 24.61% and 49.74% 
respectively). The accumulation of Co Q10 in rat epidermis from the optimised Q10-NLC formulation 
(particle size 151.7 ± 2.31) was also 10 times greater than from the emulsion. NLC and SLN are 
reported to have a similar mechanism of permeation enhancement, via occlusion and mixing 
between the formulation and stratum corneum lipids, however the liquid lipid component in NLC 
increases solubilization and thereby loading of the active, resulting in greater skin deposition. 
Improved skin deposition has been demonstrated for a number of compounds including tacrolimus 
[143, 144], psoralen [145], methotrexate [146], miconazole nitrate [147], fluocinolone acetonide 
[148] and 5-amino levulinic acid [149]. 
 
Singh‟s group has investigated surface modification for enhancing delivery and targeting of 
NLC to the skin [150-152]. NLC with the cell-penetrating peptide transactivating 
transcriptional activator (TAT-NLC) showed greater epidermal deposition of a fluorescent 
probe and the lipophilic drug celecoxib, compared to control NLC, that were located mainly 
in the hair follicles following topical administration to rat skin in vitro [150, 151]. They 
subsequently showed that surface modification of the NLC with a cell penetrating peptide 
containing 11 arginines had significantly greater permeation enhancing ability compared to 
other polyarginines and TAT peptides [152]. 
 
4.2.3. Flexible nanovesicles  
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Flexible liposomes or vesicles are composed of materials that will aggregate into bilayer 
structures but have the ability to deform in shape. Cevc‟s original Transfersomes® were 
composed of phosphatidylcholine with the surfactant sodium cholate included as an „edge 
activator‟ to confer flexibility, allowing the spherical shape to elongate and potentially 
squeeze through narrow channels relative to the their spherical diameter [153-155]. Based on 
the principals of conferring flexibility to the bilayer structure and/or incorporating 
components that are known to act as skin penetration enhancers, various vesicle compositions 
have been developed and their skin permeation quantified. These include ethosomes 
(phospholipids with a high proportion of ethanol) [13, 156-160], niosomes (flexible non-ionic 
surfactant vesicles) [161-166], invasomes (phosphatidylcholine, ethanol and a mixture of 
terpene penetration enhancers) [167-169], SECosomes (surfactant, ethanol and cholesterol) 
[14, 170] and PEVs (penetration enhancer containing vesicles) [171, 172]. Many different 
components including chemical penetration enhancers have been investigated including oleic 
acid, limonene [171, 173], propylene glycol [156, 174], glycerol [175], transcutol [176]. 
Flexible nano-vesicles have shown effective skin penetration enhancement of many 
compounds that have very poor passive permeation. For example, Dragicevic-Curic and Fahr 
[177] recently reviewed the area of flexible vesicle delivery for topical photodynamic therapy 
(PDT), which involves the delivery of a photosensitizer compound to cancer cells within the 
skin, followed by light activation to kill the cells. Photosensitizer compounds, such as 5-
amino levulinic acid and temoporfin (mTHPC), have very poor passive permeation, and the 
aim in PDT is to target the skin whilst minimising systemic uptake. Dragicevic-Curic et al 
[178] showed that an enhancement ratio of 3.4 and 2.2 for mTHPC delivery into the skin 
could be achieved with invasomes (phosphatidylcholine, ethanol and terpenes) compared to 
conventional liposomes and ethanol containing vesicles respectively. They also showed that 
the choice of terpene significantly influenced skin deposition, with cineole being superior to 
limonene, citral and mixtures of these terpenes. They also showed that the surface charge of 
flexible liposomes (composed of neutral, anionic and cationic lipids, and polysorbate 20 
surfactant) effects the physicochemical properties, stability and permeation in human 
epidermal membranes in vitro [169].  Skin deposition of mTHPC was enhanced by all 
flexible vesicles in the following order: cationic > neutral > anionic > conventional 
liposomes, with the suggestion that the cationic lipids most effectively inteact with the 
negatively charged stratum corneum. In work by Geusens et al. (Figure 11), cationic ultra-
flexible 58 nm nanosomes (SECosomes) were shown to deliver siRNA into the viable 
epidermis with deposition monitored by multiphoton tomography in combination with 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 18 
fluorescence lifetime imaging microscopy (MPT-FLIM) [14]. SECosomes were composed of 
the cationic lipid 1,2-dioleoyl-3- trimethylammonium propane chloride (DOTAP), 
cholesterol, sodium cholate and 30% ethanol. Images showed human epidermal delivery of 
siRNA after 1h and NADH lifetime changes in the epidermal tissue, that suggest cell 
penetration of the fluorescent siRNA.  
 
Bracke et al [170] have applied the SECosome approach to the delivery of siRNA to target 
human beta defensin (hBD-2), which is highly up-regulated in psoriasis and has been defined 
as a biomarker for the condition.  DEFB4-siRNA-containing SECosomes, targeting hBD-2, 
was applied in a bioengineered skin-humanized mouse model for psoriasis. The authors 
reported a significant improvement in the psoriatic phenotype, normalization of the skin 
architecture and a reduction in the number and size of blood vessels in the dermal 
compartment. SECosome treatment lead to recovery of transglutaminase activity, filaggrin 
expression and stratum corneum appearance that was similar to normal regenerated human 
skin. Further support to the work of Geusens  was reported in 2016 by Dorrani et al. [179], 
who showed that passive application of small (~75 nm) liposome:siRNA complexes could 
deposit siRNA as deeply as the upper dermis of human cadaver skin. Significantly, no labeled 
liposomes or siRNA was detected in the receptor compartment of the Franz cells in which the 
study was done, suggesting that the lipoplexes did not travel beyond the dermis but deposited 
their cargo locally.  Furthermore, they were able to show that the lipoplexes could internalize 
into melanoma cells in culture, knock down BRAF expression and inhibit melanoma cell 
proliferation.   
There are a number of proposed mechanisms by which nanovesicle systems enhance skin 
permeation. One mechanism is that the vesicles disintegrate on the skin surface and their 
components penetrate into the stratum corneum, mixing with and modifying the lipid bilayers 
and thereby indirectly enhancing permeation [180]. Many of the oil and surfactant 
components of flexible vesicles are known to disrupt the stratum corneum lamellae to 
facilitate skin transport [181]. Another theory proposed by Cevc [16], and supported by other 
colleagues [182], is that the intact flexible vesicles can penetrate into and through the stratum 
corneum due to the transepidermal osmotic gradient, carrying their payload into the skin. The 
composition of the vesicle must be such that the molecules within the vesicle bilayer can 
adjust to allow the vesicle to deform to the shape of a pore within the stratum corneum. This 
is achieved because edge-active molecules such as surfactants or short-chain alcohols can 
concentrate at the sites of greatest curvature [17, 183]. However, recent evaluations of vesicle 
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skin interactions using the high resolution technologies of multiphoton excitation 
fluorescence microscopy imaging and cross correlation-raster image correlation spectroscopy 
(CC-RICS) [180] and stimulated emission depletion microscopy (STED) and CC-RICS [184] 
have failed to show evidence of intact vesicles within the skin. STED provides image 
resolution to 20 nm, whilst CC-RICS allows tracking of two fluorescent probes so that intact 
vesicles can be resolved. In the latter study, vesicles and flexible vesicles incorporating 
sodium cholate (mean diameter 96 nm) were applied unoccluded to freshly excised human 
skin for 4-8 h, then imaged. Images showed that for both vesicles and flexible vesicles, a 
large number of intact vesicles remained at the skin surface, particularly in the skin furrows, 
with very few intact vesicles in the stratum corneum. A much higher proportion of vesicles 
than flexible vesicles remained intact on the skin surface, and there was significantly more 
fluorescent probe in the deeper layers of the stratum corneum for the flexible vesicles. As the 
fluorescent signal was not associated with any vesicle-like shape, the authors concluded that 
the flexible vesicle components were contributing to the penetration enhancement. They also 
suggested that the penetration of intact flexible vesicles shown in earlier studies was due to 
the choice of mouse skin with its thinner stratum corneum. 
5. Physical enhancement and combinational methods for facilitated-delivery 
Normally, when the stratum corneum is intact and the skin barrier is uncompromised, dermal 
and transdermal delivery is limited to molecules that are relatively lipophilic, small and 
uncharged.  Consequently, many potentially useful therapeutic peptides, proteins, vaccines, 
gene fragments or drug-carrying particles are excluded.  In efforts to extend the range of 
potential skin deliverables, various active technologies that apply physical forces to overcome 
the skin barrier, utilizing acoustic, electrical, or electromagnetic energy (e.g. laser radiation or 
radiofrequencies) and high pressure have been extensively investigated over several decades 
[185, 186].  Techniques include iontophoresis, sonophoresis, thermal and radiofrequency 
ablation, laser assisted delivery and jet propulsion systems, as well as microneedles, which 
directly breach the stratum corneum.  However, despite this level of research interest, FDA 
approvals for device assisted transdermal delivery of molecules have been few (5 between 
1979 and 2013) [187].  Furthermore, commercial development of transdermal devices has 
mainly been in the area of iontophoresis (e.g. Ionsys® and Zecuity®, both FDA-approved for 
fentanyl and sumatriptan delivery respectively and others).  A few products used other 
technologies such as thermal ablation (e.g. the PassPort® patch developed by Altea 
Therapeutics, later acquired by Nitto Denko Technicla Corp.), radiofrequency ablation (e.g. 
the ViaDerm® system by TransPharma Medical Ltd.), lasers (e.g. the EpitureTM system 
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developed by Norwood Abbey), jet propulsion (e.g. Mini-JectTM by Valeritas and the 
PowderJect® system) and direct heat application (Controlled Heat-Assisted Drug Delivery 
(CHADD™) technology).  The SonoPrep® system, developed by Sontra, used low frequency 
ultrasound to deliver lidocaine for local analgesia.  This was the only low frequency 
sonophoresis system on the market but has since been withdrawn.  
 
Further enhancement and even synergistic transdermal delivery has been achieved with a 
combination of techniques, including an active technology with chemical permeation 
enhancers [188] or two active technologies [189]. Of particular interest is the combination of 
microneedle delivery with active technologies such as iontophoresis [190] or sonophoresis 
[191].  Here, the goal is to use the microneedles to accurately place the deliverable at a 
specific target site and to use the second active technology to enhance its release and 
distribution.  Donnelly et al. [190] showed enhanced delivery of peptides and proteins with 
the combination of iontophoresis and hydrogel-forming microneedle arrays and suggested 
that the technique may more useful for macromolecules than small molecules which are 
already delivered efficiently by microneedles alone.  While the use of combination 
technologies may offer enhanced delivery with improved control over delivery rates, along 
with some degree of specific targeting in the case of microneedles, they are also currently 
associated with greater complexity, cost and difficulty of use.  If they are to achieve 
widespread acceptance and use, it will be necessary to harness advances in device design and 
fabrication to make them more refined and inexpensive. 
 
6. Safety and adverse effects 
As discussed in Section 3, there is concern that penetration of biopersistent solid 
nanoparticles into the skin could lead to damage to viable epidermal cells or accumulation in 
secondary organs following biodistribution [70].  Examples of such materials include gold, 
silver, metal oxides such as titanium dioxide and zinc oxide, quantum dots, fullerenes and 
carbon nanotubes.  Consequently, rigorous risk assessment is required for these [192].  Also 
falling into the biopersistent category are the environmental hazards such as clay particles 
absorbed though skin of bare feet [80] or skin-absorbed beryllium [64].  There is less concern 
over colloidal nanosystems such as emulsions and lipid-based materials because these are 
likely to be biodegradable on application to the skin, although the molecular products will 
still be assessed in the usual way for irritancy and cytotoxicity.  For example, Todosijević et 
al. [193] used changes in erythema index, skin hydration and TEWL to assess the skin 
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irritancy of different microemulsion formulations containing natural and synthetic non-ionic 
surfactants for delivery of a model NSAID and showed that irritancy was strongly associated 
with the presence of Polysorbate 80 and Transcutol P.  Gürbüz et al. [194] assessed the 
cytotoxicity of microemulsions for isotretinoin delivery using the MTT assay with a mouse 
fibroblast cell line, comparing the microemulsions to SLS as a positive control.  Standard 
techniques to assess cell viability with mouse or human cell lines have also been used for 
lipid-based vesicles [195, 196] and ultraflexible liposomes [14, 197].  Raju et al. used 
multiphoton imaging of fluorescence following staining by acridine orange and ethidium 
bromide to demonstrate cell viability or death in response to interventions by delivery devices 
such as gene guns [198].  These workers showed that ballistic delivery of gold microparticles 
coated with DNA vaccine at densities of 0.16, 1.35 and 2.72 particles per m
2
 to freshly 
excised mouse ear skin resulted in cell death rates of 3.96, 45.91 and 90.52% respectively.  
The results raised questions about the safety of this technique and the authors suggested that 
successfully optimized transfection with this device would require a compromise between the 
payload density and the inevitable level of cell death.   
 
7. Future developments 
We are constantly facing new challenges in skin delivery and as we have seen, extensive 
research is being undertaken to develop novel and improved delivery systems.  For example, 
a recent sunscreen formulation uses bioadhesive nanoparticles with limited skin penetration 
to prevent epidermal cell exposure to potentially toxic chemical UV filters, at the same time 
providing enhanced UV protection [199].  As Vogt et al. have recently pointed out, a 
worthwhile nanodelivery system should offer significant advantages, such as easier 
application, reduced systemic absorption and enhanced selectivity to diseased skin or specific 
cell populations, compared to more traditional methods [200].  We would add that, in our 
view, the development of dermal and transdermal nanodelivery systems should be driven by a 
clinical or therapeutic need, rather than by the availability of advanced technology.  One such 
clinical need is the long sought after, but highly elusive goal of non-invasive insulin delivery.  
Nanodelivery strategies being explored for this hydrophilic macromolecule include a patch 
consisting of a polymeric nanotube backbone to which insulin is electrostatically bound 
[201].  An electric potential is then applied to release the bound insulin. The potential is also 
hypothesized to drive the drug into the skin, analogous to iontophoresis.  Another important 
clinical application of nanodelivery systems is likely to be needle free transcutaneous 
immunization, particularly by the hair follicle route [202]. 
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The next generation of nanocarriers will be designed to release their drug payload in response 
to certain chemical, physical or biological stimuli, allowing much greater precision in 
delivery to particular targets – the so-called “Smart” nanosystems.  Much work is already 
being carried out on intravenous or orally administered drug or gene delivery systems that are 
responsive to temperature, UV or IR radiation, ultrasound or pH [203].  For example, smart 
nanocarriers that can accumulate in tumors after intravenous injection have been developed 
which combine pH-triggered doxorubicin release and near infrared light-triggered 
photosensitization to provide dual chemotherapy and photodynamic therapy [204].  New skin 
penetrating nanocarriers containing similar triggers will no doubt be developed to deliver 
deeper, faster and better-targeted skin cancer therapy than that currently available with 
creams containing aminolevulinic acid (ALA) or its methyl ester (MAL). 
 
As we have already seen, the Lademann group has explored follicular delivery of 
nanoparticles and hypothesized that these appendages may act as a reservoir for a drug 
payload [92].  Up to now, the difficulty has been how to initiate and control drug release, 
rather than relying on passive diffusion.  In recent work [205] they are now exploring smart 
nanoparticles for follicular delivery that are designed to release a drug after the application of 
specific stimuli.  Three nanoparticle systems were developed, where model drug release 
occurred by passive diffusion through a porous surface, in response to enzymatic degradation 
of the encapsulating particle and after photoactivation by infrared radiation.  Deep follicular 
penetration of the model drugs, as well as uptake by sebaceous glands was seen with the 
latter two active release mechanisms. 
 
8. Conclusion 
Our observation is that nanodelivery systems show great promise, provided that they 
are optimally matched to their designed purpose, rather than simply being seen as “one 
technology fits all” applications.  With this in mind, it should also be recognised that 
nanosystems may not necessarily be the most efficient way to solve a particular problem. 
Vogt et al. [200] recently alluded to this, citing the example of treating scalp diseases, where 
nanoparticles may not be required for follicular penetration. However, the evolutionary 
development in these systems is likely to continue, with a greater focus on solving difficult 
skin delivery problems, by developing smart materials to deliver peptides, proteins and 
genetic material with accurate targeting to specific cell populations.  As nanosystems are 
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refined, emphasis will need to be placed on those that can be translated to clinical application 
and which provide significant economic and patient benefits. 
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Figure Legends 
Figure 1. Nanodelivery systems investigated for dermal and transdermal drug delivery. 
 
Figure 2. Structure of human skin, showing major structures and cell types.  Skin layer 
thicknesses (not drawn to scale) are approximations only and actual values vary according to 
the anatomical site and factors such as the degree of hydration. 
 
Figure 3. Properties of nanosystems determining skin absorption and potential routes of 
penetration (skin layer thicknesses not drawn to scale). 
 
Figure 4. Gold-based nanoparticle penetration into rat, pig and human skin. 
 
Figure 5. Quantum dots with various external functional groups penetrating to deeper layers 
in excised pig skin (A), but remaining on the surface or localized in furrows in excised human 
skin (B). 
A: Confocal scanning microscopy of porcine skin treated for 8 h with PEG, PEG-amine 
(NH2), or carboxylic acid (COOH)-coated QD 565. Coatings are noted at the top of each 
column. Top row: confocal-DIC channel only allows an unobstructed view of the skin layers. 
Middle row: confocal-DIC overlay with the QD fluorescence channel (green) shows QD 
localization within the skin layers. Arrows indicate QD localization in the epidermis or 
dermis. Bottom row: fluorescence intensity scan of QD emission. Quantum dots 565 are 
localized in the epidermal (PEG and COOH coatings) or dermal (NH2 coating) layers by 8 
h. All scale bars (lower right corners) are 50 µm. 
J.P. Ryman-Rasmussen et al. Toxicol Sci 91 (2006) 159-165 Reproduced with permission. 
[63] 
B: LSCM images of untreated intact human skin or skin treated with PEG, PEG-NH2 and 
COOH modified QDs at pH 7.0, for 24 h in static Franz cells. The QDs (red) at pH 7.0 can be 
seen primarily on the stratum corneum and in skin furrows (arrow heads). Skin reflectance 
(green) reveals nuclei as dark ellipsoids, with no QDs within the stratum granulosum or 
spinosum. Scale bar indicates 100 mm; the optical section thickness was estimated as 2 mm. 
T.W Prow et al. Nanotoxicology 6 (2012) 173-185 Reproduced with permission. [61] 
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Figure 6. Confocal microscopic images of skin, showing penetration of FITC-conjugated 
dextran beads (red). Images were obtained from the centre of the tissue cross section at a 
depth of 10 μm. (A) 1 µm beads were observed at the stratum corneum–epidermal interface 
and in the epidermis following 30 min of flexure (blue arrows). (B) 1 µm beads were 
observed at the stratum corneum–epidermal interface and in the epidermis after 30 min of 
flexure, and in the epidermis and dermis after 60 min (all arrows); beads were found 
randomly distributed in the tissue, and occasional clusters of beads were identified (yellow 
arrows). (C) 4 µm beads remained on the surface of the skin (tissue depth 13 μm). (D) 
Discontinuous stratum corneum permitted entry of a bolus of 0.5 μm beads into the skin 
directly under the tear (yellow arrow). Bar = 10 μm for A–D. 
S.S. Tinkle et al., Environ Health Perspect 111 (2003) 1202-1208. Reproduced with 
permission. [64]. 
 
Figure 7. Investigation of penetration of topically applied uncoated and coated ZnO 
nanoparticles in the stratum granulosum (SG) layer of in vivo human skin following 
application with flexing and massage. Representative FLIM images of SG of human skin 
following flexing (top) and massage (bottom). Images are pseudocolored to distinguish 
cellular autofluorescence (green) and the ZnO NP signal (violet-yellow-white scale bar 
representing intensity of the ZnO NP signal).  ZnO is confined mainly to the furrows and is 
not detected in the viable epidermis cellular region. 
Figure derived from data in V.R. Leite-Silva et al., Nanomedicine (Lond.) 11 (2016) 1193-
1205. [59]. 
 
Figure 8. Representative multiphoton images of intact and barrier-impaired in vivo human 
skin; (A) without occlusion and (B) with occlusion.  
Images were measured 6 h after topical application of the vehicle control (CCT), uncoated or 
coated ZnO NP (100 mg.mL
−1
; 2 mg.cm
−2
) on intact (In) and barrier-impaired (BI) skin 
(tape-stripped 20 times), with and without occlusion. The white dotted box shows ZnO NP 
signals detected within the BI viable epidermis (VE). The white scale bar represents a length 
of 40 μm.  Figure derived from data presented in V.R. Leite-Silva et al., Eur J Pharm 
Biopharm 104 (2016) 140-147. [1]. 
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Figure 9.  Application of ZnO nanoparticles to A: excised human skin and B-D: lesional and 
non-lesional skin of psoriasis patients. 
A: Electron micrographs of excised intact human skin showing ZnO nanoparticles present on 
the surface of the skin and around desquaming corneocytes. No penetration into the 
underlying intact stratum corneum was observed. 
S.E. Cross et al. Skin Pharmacol Physiol 20 (2007) 148-154. Reproduced with permission. 
[56]. 
B: Treatment areas in lesional and non-lesional areas of forearms in psoriasis patients. 
C: Minimal pixel intensities in lesional and non-lesional skin below the stratum corneum, 
derived from the FLIM spectra shown in D. 
D: Penetration profile of zinc oxide nanoparticles in skin furrows. Panels a and b show 
untreated lesional (a) and zinc oxide nanoparticle containing sunscreen treated lesional sites 
(b). The inset in panel b is an electron microscopy image of the individual zinc oxide 
nanoparticles with a mean diameter of 35 nm, the bar indicates 100 nm. T.W. Prow et al., 
Adv Drug Deliv Rev 63 (2011) 470-491. Reproduced with permission. [70] 
 
Figure 10. Penetration of particles into hair follicles; effect of massage and hair removal. 
A: Superimposed transmission and fluorescent images showed in vitro penetration of a dye-
containing formulation into intact hair follicles of porcine skin with and without massage. 
Deeper penetration occured when the dye was in particle form. 
J. Lademann et al. Eur J Pharm Biopharm, 66 (2007) 159-164. Reproduced with permission. 
[66] 
B: After hair removal by application of superglue, followed by massage of the applied 
formulations into human hair follicles, 40 nm, but not 750 nanoparticles penetrated via the 
vellus hair follicle and were internalized by Langerhans cells in surrounding tissue. 
(i, ii) 40 nm nanoparticles penetrated deep into vellus hair follicles. Laser scan microscopy 
revealed fluorescent signals in adjacent tissue (*), indicating that nanoparticles penetrated 
into and through the follicular epithelium.  
Transcutaneously applied (iii, iv) 750 nm fluorescent nanoparticles aggregated in the 
infundibulum of human vellus hair follicles. No penetration to deeper parts of the hair 
follicles and no penetration into viable epidermis was observed in any of the samples. A. Vogt 
et al. J Invest Dermatol, 126 (2006) 1316-1322. Reproduced with permission. [99] 
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Figure 11. Penetration of ultraflexible vesicles (SECosomes) through excised human skin.  
A: Overlaid TEM and confocal images excited at 639 nm from skin biopsy cross sections. 
Untreated skin is shown in (a) and the red fluorescence signal due to the Cy5-siRNA 
indicates penetration of complexes with surfactant containing liposomes (b, SCLPX), 
ethanolic liposomes (c, ELPX) and ultraflexible SECosomes (d, SECoplexes). The strongest 
signal comes from SECoplexes. 
B: Multiphoton microscopy images showing enhanced SECoplex penetration around 
keratinocytes at a depth of 40 μm (enlarged in C, left). 
C: (right) To confirm whether the complexes are taken up by the cells, time-resolved NADH 
autofluorescence spectra (free and bound) were obtained using FLIM following excitation at 
740 nm. A shift in fluorescence lifetime was observed compared to normal untreated skin 
(blue line), confirming the presence of the SECoplexes (red line) inside the cells. 
B. Geusens et al. et al. Adv Funct Mater, 20 (2010) 4077-4090. Reproduced with permission. 
[14] 
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Table 1. Scope of the field of topical and cutaneous delivery using nanosystems. 
Nanosystem use Dermatologicals, vaccines, diagnostic agents, cosmetics 
Target sites Surface, Skin, Systemic 
Product range Nanoparticles, nanoemulsions, nanovesicles 
Chemical adjuncts Formulation enhancers, Skin pretreatment 
Physical adjuncts Electrical, sound, electromagnetic, physical, other technologies 
Efficacy Able to facilitate cargo penetrating in sufficient quantities? 
Safety Major area of concern from regulators and consumers 
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Table 2. Properties of nanodelivery systems in use or under development 
Type of Nanosystem Possible mode of action Advantages Disadvantages 
Solid nanoparticles 
Zinc oxide and titanium 
dioxide nanoparticles 
Zinc oxide and titanium dioxide nanoparticles are 
mainly used in sunscreens because of their ability to 
filter UVA and UVB radiations 
Nanoparticles < 100nm in size are 
invisible, while retaining sun screening 
properties; Current evidence suggests 
they remain localized in the stratum 
corneum of the skin with no permeation 
observed in the viable epidermis [1, 2] 
In vitro toxicity seen in cell 
cultures [3]; Controversy 
surrounding skin permeation.  
Liquid colloidal systems 
Microemulsions Disruption of SC lipid organization due to the 
formulation components such as surfactants, co-
surfactants and oils [4].) 
Thermodynamically more stable 
compared to macroemulsions and 
efficient solubilisation of the active in 
the formulation. 
Stability influenced by factors such 
as pH & temperature changes; 
Potential for skin irritation due to 
high concentration of surfactants. 
Nanoemulsions 
 
Solubilization/extraction of stratum corneum lipids 
due to the components used in nanoemulsion, 
thereby decreasing resistance for drug transport [5]. 
Isotropic, transparent, kinetically stable; 
high solubilization capacity for both 
lipophilic & hydrophilic drugs [6] 
Careful selection of formulation 
components essential to avoid skin 
irritation 
Vesicular carriers 
Solid Lipid nanoparticles Solid lipid nanoparticles reported to deform in shape 
and melt after application to skin reducing the skin 
barrier and causing occlusion on the skin surface 
favoring the penetration of the active [7, 8]. 
 
Incorporation of lipophilic and 
hydrophilic drugs, low cost compared to 
liposomes and ease of scale-up and 
manufacturing. Lipid matrix composed 
of physiological lipids exhibiting low 
toxicity [9]. 
Poor stability and low drug loading. 
Liposomes Numerous studies have been undertaken to elucidate 
the mechanism of action of liposomes. A general 
mode involves adhesion of the liposomes on the skin 
surface followed by release of the active from the 
liposomal structure. The phospholipids and 
surfactants included in the formulation may act as 
Ability to encapsulate a wide range of 
hydrophilic or hydrophobic drugs, good 
biocompatibility, low toxicity, and 
targeted delivery of drugs to the site of 
action [11, 12]. 
Poor stability and limited 
penetration in the upper layers of 
the stratum corneum [13]. 
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penetration enhancers [10].  
Secosomes 
(combination of 
DOTAP, Na cholate, 
cholesterol, ethanol) 
Leaching of stratum corneum lipids leading to 
migration of secosomes in the skin fissures and 
uptake by keratinocytes [14]. 
Enhanced skin penetration due to 
ultradeformability [14, 15]. 
Novel delivery system with limited 
research undertaken. 
Transferosomes Destabilization & increase in deformability by 
lowering interfacial tension of lipid bilayers [16]. 
Elastic vesicles capable of permeating 
intact skin [16]. 
Emulsifiers (edge activators) must 
be high purity to avoid risk of skin 
irritation & toxicity  
Ethosomes Fluidization of the lipid bilayers due to an edge 
activator or alcohols which also enhance the 
deformability of the vesicles [17]. 
Increase in stability and enhancement in 
transdermal permeation compared to 
conventional liposomes. High loading 
capacity for lipophilic drugs compared 
to liposomes; relatively simple & 
inexpensive to manufacture. 
Skin irritation due to high 
concentration of alcohol and poor 
skin penetration. 
Microneedles  Minimally invasive and act by creating microscopic 
aqueous pores through which molecules can gain 
access to the dermal circulation without stimulating 
the dermal nerves or puncturing the dermal blood 
vessels [18]. 
Obvious advantages over traditional 
patches in terms of delivery of actives. 
Possibility of delivering larger peptides, 
proteins and vaccines non-invasively 
through skin [18]. 
Problems in processing & storage 
with sugar-based microneedle 
arrays; Thermal treatment during 
manufacture can restrict type of 
active loaded into arrays; 
Evaluation of biocompatibility of 
all microneedle materials with skin 
required; Regulatory issues should 
be considered due to 
innovativeness of delivery mode 
[19]. 
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Table 3. Examples of recently published studies reporting the in vivo evaluation of topically 
applied nanosystem formulations for the management of skin disorders. 
Nanosystem Drug delivered Skin disorder Reference 
Lipid-based nanosystems    
Liposome Curcumin Melanoma [20] 
Ethosome gel Mitoxantrone Melanoma [21] 
 Quercetin Inflammation [22] 
 Amphotericin B 
Fungal infection 
(Candida albicans) 
[23] 
Liposome, ethosome & 
deformable liposome 
Ketoconazole 
Fungal infection 
(Candida albicans) 
[24] 
NLC-based gel Clobetasol propionate Eczema [25] 
SLN Artemisone Melanoma [26] 
 Doxorubicin 
Squamous cell 
carcinoma 
[27] 
Polymer-based nanosystems    
Polymeric chitosan NP 
Hydrocortisone/Hyroxytyros
ol (co-administration) 
Atopic dermatitis [28, 29] 
PLGA NP Pranopofen Inflammation [30] 
Lipid-polymer hybrid NP Lidocaine Pain [31] 
Metal-based nanosystems    
NP Silver 
Scalp fungal infection 
(Malassezia furfur) 
[32] 
 Gold Psoriasis [33] 
Surfactant-based nanosystems     
Niosomes Artemisone Melanoma [26] 
Oil-in-water ME Caffeine 
UVB-induced skin 
cancer 
[34] 
Water-in-oil ME Pentoxifylline Inflammation [35] 
Ionic liquid-in-water ME Etodolac Infllammation [36] 
Hydrogel-thickened ME Ibuprofen Inflammation [37] 
ME = microemulsion; NLC = Nanostructured lipid carrier; NP = nanoparticle; PLGA = 
poly(lactic-co-glycolic acid); SLN = Solid lipid nanoparticles  
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